CN111615519A - 结合人il-5的单克隆抗体、其制备方法和用途 - Google Patents

结合人il-5的单克隆抗体、其制备方法和用途 Download PDF

Info

Publication number
CN111615519A
CN111615519A CN201880081391.0A CN201880081391A CN111615519A CN 111615519 A CN111615519 A CN 111615519A CN 201880081391 A CN201880081391 A CN 201880081391A CN 111615519 A CN111615519 A CN 111615519A
Authority
CN
China
Prior art keywords
monoclonal antibody
seq
human
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880081391.0A
Other languages
English (en)
Other versions
CN111615519B (zh
Inventor
赵杰
黄浩旻
朱祯平
蒋良丰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Original Assignee
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Guojian Pharmaceutical Shanghai Co Ltd filed Critical Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Publication of CN111615519A publication Critical patent/CN111615519A/zh
Application granted granted Critical
Publication of CN111615519B publication Critical patent/CN111615519B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

本发明公开了一种结合人IL‑5的单克隆抗体，具有良好的抑制IL‑5诱导的TF‑1细胞增殖以及阻断IL‑5与IL‑5RA的相互作用的生物学活性，并且具有与已知的抗人IL‑5抗体不同的抗原表位，可应用于制备治疗嗜酸性粒细胞过表达介导的疾病(例如哮喘)的药物，具有良好的临床应用前景。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN201880081391.0A 2017-12-21 2018-11-30 结合人il-5的单克隆抗体、其制备方法和用途 Active CN111615519B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017113931471 2017-12-21
CN201711393147.1A CN109942706A (zh) 2017-12-21 2017-12-21 结合人il-5的单克隆抗体、其制备方法和用途
PCT/CN2018/118534 WO2019120060A1 (zh) 2017-12-21 2018-11-30 结合人il-5的单克隆抗体、其制备方法和用途

Publications (2)

Publication Number Publication Date
CN111615519A true CN111615519A (zh) 2020-09-01
CN111615519B CN111615519B (zh) 2023-07-11

Family

ID=66993075

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201711393147.1A Pending CN109942706A (zh) 2017-12-21 2017-12-21 结合人il-5的单克隆抗体、其制备方法和用途
CN201880081391.0A Active CN111615519B (zh) 2017-12-21 2018-11-30 结合人il-5的单克隆抗体、其制备方法和用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201711393147.1A Pending CN109942706A (zh) 2017-12-21 2017-12-21 结合人il-5的单克隆抗体、其制备方法和用途

Country Status (5)

Country Link
US (1) US11370836B2 (zh)
EP (1) EP3730518A4 (zh)
JP (1) JP7032534B2 (zh)
CN (2) CN109942706A (zh)
WO (1) WO2019120060A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114907485A (zh) * 2021-02-08 2022-08-16 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
CN117209603A (zh) * 2021-12-02 2023-12-12 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112745389B (zh) * 2019-10-29 2022-11-25 瑞阳(苏州)生物科技有限公司 结合人il-5的单克隆抗体及其应用
CN111471655B (zh) * 2020-03-19 2023-07-07 湖州正熙医学检验实验室有限公司 抗人il12/23稳转细胞株及其构建方法和应用
CN113769081A (zh) * 2020-06-10 2021-12-10 三生国健药业（上海）股份有限公司 一种稳定的高浓度抗人il-5单克隆抗体液体制剂

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004979A2 (en) * 1988-11-03 1990-05-17 Schering Corporation Method of preventing or reducing eosinophilia
CN1077991A (zh) * 1992-02-06 1993-11-03 先灵公司 具有人属性的抗人白细胞介素-5的单克隆抗体的设计，克隆和表达
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US20040265957A1 (en) * 1998-08-13 2004-12-30 Angel Lopez Monoclonal antibody inhibitor of GM-CSF, IL-3, IL-5 and other cytokines, and uses thereof
CN103429261A (zh) * 2010-12-22 2013-12-04 塞法隆澳大利亚股份有限公司 半寿期改进的修饰抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
JP2001523083A (ja) * 1994-12-23 2001-11-20 スミスクライン・ビーチャム・コーポレイション Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
US7399837B2 (en) * 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US6018032A (en) 1995-09-11 2000-01-25 Kyowa Hakko Kogyo Co., Ltd. Antibody against human interleukin-5-receptor α chain
DK1527100T3 (da) 2002-03-29 2009-09-07 Schering Corp Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme
US20100086547A1 (en) * 2007-04-30 2010-04-08 Smithkline Beecham Corporation Methods for administering anti-il-5 antibodies
HUE036885T2 (hu) 2007-05-14 2018-08-28 Astrazeneca Ab Eljárás a bazofil-szint csökkentésére
ES2729422T3 (es) * 2009-05-28 2019-11-04 Glaxo Group Ltd Proteínas de unión al antígeno

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004979A2 (en) * 1988-11-03 1990-05-17 Schering Corporation Method of preventing or reducing eosinophilia
CN1077991A (zh) * 1992-02-06 1993-11-03 先灵公司 具有人属性的抗人白细胞介素-5的单克隆抗体的设计，克隆和表达
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US20040265957A1 (en) * 1998-08-13 2004-12-30 Angel Lopez Monoclonal antibody inhibitor of GM-CSF, IL-3, IL-5 and other cytokines, and uses thereof
CN103429261A (zh) * 2010-12-22 2013-12-04 塞法隆澳大利亚股份有限公司 半寿期改进的修饰抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JI ZHANG等: "Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5" *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114907485A (zh) * 2021-02-08 2022-08-16 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
CN114907485B (zh) * 2021-02-08 2024-04-26 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
CN117209603A (zh) * 2021-12-02 2023-12-12 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117209603B (zh) * 2021-12-02 2024-02-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用

Also Published As

Publication number Publication date
CN109942706A (zh) 2019-06-28
EP3730518A1 (en) 2020-10-28
US20210171621A1 (en) 2021-06-10
JP2021505183A (ja) 2021-02-18
US11370836B2 (en) 2022-06-28
JP7032534B2 (ja) 2022-03-08
CN111615519B (zh) 2023-07-11
EP3730518A4 (en) 2022-03-09
WO2019120060A1 (zh) 2019-06-27

Similar Documents

Publication Publication Date Title
JP7142618B2 (ja) イヌ化抗体
US20210040223A1 (en) Antibodies to Canine Interleukin-4 Receptor Alpha
US11370836B2 (en) Monoclonal antibody binding to human IL-5, preparation method therefor and use thereof
CN108409860B (zh) 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用
EP4289861A1 (en) Antibodies against human tslp and use thereof
CN112041347B (zh) 结合人il-4r的抗体、其制备方法和用途
US11939387B2 (en) Anti-human interleukin-4 receptor alpha antibody and preparation method and application thereof
EP3683234A1 (en) Il-6r antibody and antigen binding fragment thereof and medical use
WO2019096219A1 (zh) 一种人源化抗il-13抗体及其制备方法和应用
WO2023078382A1 (zh) 结合gprc5d的抗体及其用途
TWI801425B (zh) Il-5 抗體、其抗原結合片段及醫藥用途
JP2023523794A (ja) 人工操作免疫グロブリン
WO2021218574A1 (zh) 结合人ngf的抗体、其制备方法和用途
RU2807060C1 (ru) Антитело к альфа-рецептору интерлейкина-4 человека, способ его получения и его применение
WO2024002145A1 (zh) 结合il-17a和il-17f的抗体分子及其应用
WO2023051656A1 (zh) 双特异性抗体及其应用
CN117886935A (zh) 抗csf-1r抗体及其应用
CN116848144A (zh) 抗pd-l1抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant